BioSpace News Archive

Drug Development

Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration

Stealth BioTherapeutics Inc. announced the successful and favorable outcomes of an end-of-phase 2 meeting with the U.S. Food and Drug Administration for elamipretide, its lead drug candidate for the treatment of dry age-related macular degeneration.

June 12, 2023
·
5 min read
Biotech Bay

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

Nektar Therapeutics’ senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 1:20 p.m. Pacific Time.

June 12, 2023
·
1 min read
Business

Labcorp Announces Additional Information in Connection With Its Spin-off of Fortrea

Labcorp, a leading global life sciences company, previously announced the following record and distribution dates for its spin-off of Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp.

June 12, 2023
·
4 min read
Business

Biogen Announces Changes to Its Board of Directors

Biogen Inc. announced several changes to its Board of Directors. The changes will refresh the composition of the Board and follow the Board’s continual interaction with company stockholders to solicit their perspective on a range of issues around the company’s performance and strategy.

June 12, 2023
·
6 min read
Business

Labcorp Announces Pricing of Fortrea $570 Million Notes Offering in Connection With Anticipated Fortrea Spinoff

Labcorp, a leading global life sciences company, announced that Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp, has priced an offering of $570 million of senior secured notes due 2030, in connection with the previously announced spinoff of Fortrea into a separate publicly traded company.

June 12, 2023
·
5 min read
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness

Beacon Therapeutics Holdings Limited, a leading ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with retinal diseases, launches and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness.

June 12, 2023
·
7 min read
Drug Development

Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Oxurion NV announced that it has randomized the last patient in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema .

June 12, 2023
·
5 min read
Business

Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations

Metrion Biosciences Ltd, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment.

June 12, 2023
·
2 min read
Policy

US FDA Grants for Over-the-Counter Marketing Authorization to Futura for Fast-Acting Topical Gel, MED3000, to Treat Erectile Dysfunction

Futura Medical plc announces that the US Food and Drug Administration has granted over the counter sale Marketing Authorisation for MED3000, the Company’s breakthrough, topical gel formulation for the treatment of erectile dysfunction as a De Novo Medical Device.

June 12, 2023
·
4 min read
China Medical System: The first ‘Diazepam Nasal Spray’ Approved for Marketing in China

On June 12, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on June 7 2023, the New Drug Application (NDA) of Diazepam Nasal Spray (the “Product”) received approval from the National Medical Products Administration of China (NMPA).

June 12, 2023
·
5 min read